Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2 ‐year Clinical Trial

In conclusion, a single intravenous infusion of zoledronate given 6 months after the last Dmab injection prevents bone loss for at least two years independently of the rate of bone turnover. Follow‐up is recommended, as in a few patients ZOL treatment might not have the expected effect at 2 years.This article is protected by copyright. All rights reserved.

https://asbmr.onlinelibrary.wiley.com/doi/abs/10.1002/jbmr.3853?af=R

Source: Journal of Bone and Mineral Research - August 20, 2019 Category: Orthopaedics Authors: Athanasios D. Anastasilakis, Socrates E. Papapoulos, Stergios A. Polyzos, Natasha M. Appelman ‐Dijkstra, Polyzois Makras Tags: Original Article Source Type: research